FIRST AIRED: May 11, 2018

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!

We've got more news

Get our editor’s daily email summary of what’s going on in the world.

US Edition
Intl. Edition
Replay Program
More Info

COMING UP:Share Opener Variant 4



>> And we will have tougher negotiation, more competition, and much lower prices at the pharmacy counter. And it'll start to take effect very soon.>> In a highly anticipated speech, President Trump unveiled his blueprint Friday for lowering drug costs, and putting, quote, American patients first. The list of proposed changes was vague and complex.
But Reuters health correspondent Caroline Humer says, consumers could ultimately benefit in modest ways, if the changes ever see the light of day.>> Under consideration are 50 different things, but the ones the consumers might notice have to do with advertising. They said they would look at actually putting list prices for drugs into the advertisements that you see on TV and in print, that would be a change.
Another possible change, they said that they want to try to get the drug maker discount, which now gets sort of hung up in the healthcare system, into the hands of consumers.>> Trump also took aim at the entire healthcare industry for getting rich while making the Americans who need medicine poorer, and vowed to fix that.
>> We're going to take on one of the biggest obstacles to affordable medicine, the tangled web of special interests. No industry spends more money on lobbying than the pharmaceutical health industry. Last year, these companies spent nearly $280 million on lobbyists. That's more than tobacco, oil, and defense contractors combined.
>> But investors didn't see Trump's rollout as significantly changing the game, prompting a rally in health-related stocks across the board.